Completed PHASE2 INTERVENTIONAL 1-arm NCT02604485

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism (HI)

Sponsor: XOMA (US) LLC

Interventions Cohort 1 Cohort 2 Cohort 3 Cohort 4

Updated 6 times since 2017 Last updated: Feb 2, 2017 Started: Oct 31, 2015 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02604485, this PHASE2 trial focuses on Congenital Hyperinsulinism and remains completed. Sponsored by XOMA (US) LLC, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

XOMA (US) LLC

Data source: XOMA (US) LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom
• Philadelphia, United States